selim badur

Prof. Dr. selim badur


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Annals of Medicine
Verified
Journal Article
Open access
MOMartin O. C. Ota
Martin O. C. Ota
SBselim badur
selim badur
LRLuis Romano-Mazzotti
Luis Romano-Mazzotti
LFLeonard R. Friedland
Leonard R. Friedland
The current COVID-19 global pandemic continues to impact healthcare services beyond those directly related to the management of SARS-CoV-2 transmission and disease. We reviewed the published literature to assess the pandemic impact on existing global immunization activities and how the impact may be addressed. Widespread global disruption in routine childhood immunization has impacted a majority of regions and countries, especially in the initial pandemic phases. While data indicate subsequent recovery in immunization rates, a substantial number of vulnerable people remain unvaccinated. The downstream impact may be even greater in resource-limited settings and economically poorer populations, and consequently there are growing concerns around the resurgence of vaccine-preventable diseases, particularly measles. Guidance on how to address immunization deficits are available and continue to evolve, emphasizing the importance of maintaining and restoring routine immunization and necessary mass vaccination campaigns during and after pandemics. In this, collaboration between a broad range of stakeholders (governments, industry, healthcare decision-makers and frontline healthcare professionals) and clear communication and engagement with the public can help achieve these goals.

16 April 2020 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
SBselim badur
selim badur
MOMartin Ota
Martin Ota
SÖSerdar Öztürk
Serdar Öztürk
RARICHARD ADEGBOLA
RICHARD ADEGBOLA
ADAnil Dutta
Anil Dutta
During the 20th century, the discovery of modern vaccines and ensuing mass vaccination dramatically decreased the incidence of many infectious diseases and in some cases eliminated them. Despite this, we are now witnessing a decrease in vaccine confidence that threatens to reverse the progress made. Considering the different extents of low vaccine confidence in different countries of the world, both developed and developing, we aim to contribute to the discussion of the reasons for this, and to propose some viable scientific solutions to build or help restore vaccine confidence worldwide.

1 April 2020 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
PBPhilippe Buchy
Philippe Buchy
SBselim badur
selim badur
Known since Hippocrates and of continuing public health importance, influenza remains a major cause of morbidity and mortality worldwide, and large segments of the human population are affected every year. Vaccination is the most effective means of preventing influenza infection. Today, many countries have implemented annual influenza vaccination programs, and there is increasing awareness of the potential societal and health benefits of vaccinating pregnant women, children aged 6 months to 5 years, older adults, and persons with underlying medical conditions that make them vulnerable to serious complications of influenza. In this non-systematic review, we summarize data on influenza epidemiology and influenza vaccine immunogenicity, efficacy/effectiveness, and safety in the main high-risk groups. We also discuss the optimal time to vaccinate and the effect of pre-existing immunity on vaccine response.

17 May 2019 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
SBselim badur
selim badur
SÖSerdar Öztürk
Serdar Öztürk
PPPriya Pereira
Priya Pereira
MAMohammad AbdelGhany
Mohammad AbdelGhany
MKMansour Khalaf
Mansour Khalaf
DSDebasish Saha
Debasish Saha
Rotavirus gastroenteritis imposes a heavy burden on low- and middle-income countries. The World Health Organization defines the Eastern Mediterranean region (WHO-EMRO) as a diverse area in terms of socioeconomic status and health indicators. Rotavirus vaccination has been introduced, at least partially, in 19 out of the 22 EM countries; however, vaccine coverage remains low, and data on rotavirus disease burden is scarce. Available data on rotavirus prevalence, seasonality, vaccination status, and genotype evolution was systematically compiled following a literature review that identified 165 relevant WHO-EMRO epidemiology studies published between 1990 and 2017. Although the infectious agents responsible for acute gastroenteritis vary over time, rotavirus remained the leading cause of acute gastroenteritis in children, as seen in 76.3% of reviewed publications. Younger children (<2 years old) were at higher risk and thus increased vaccination coverage and surveillance systems are required to reduce the rotavirus gastroenteritis burden in WHO-EMRO countries.

19 May 2022 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
SBselim badur
selim badur
MKMansour Khalaf
Mansour Khalaf
SÖSerdar Öztürk
Serdar Öztürk
RARajaa Mohammad Al-Raddadi
Rajaa Mohammad Al-Raddadi
AAAshraf Amir
Ashraf Amir
ASAtef Shibl
Atef Shibl
Invasive meningococcal disease (IMD) outbreaks associated with Hajj and Umrah pilgrimage events in the Kingdom of Saudi Arabia (KSA) are well recognized. Past outbreaks have been associated with substantial intercontinental spread of specific Neisseria meningitidis serogroups. The emergence of meningococcal serogroup W (MenW) was a global concern following the 2000/2001 Hajj outbreaks. Broader compulsory meningococcal serogroups A, C, W and Y (MenACWY) immunization strategies for pilgrims were introduced in response to these events and led to substantial declines in IMD cases associated with these mass gatherings. However, there remains potential for future outbreaks either within KSA during the Hajj or in local populations via pilgrim meningococcal transmission on their return. While the annual Hajj involves pilgrims from over 185 countries, two-thirds of these arrive from 13 countries, chiefly from across South-East Asia, the Middle East and North African (MENA) regions; for which we review the relevant epidemiology of IMD and meningococcal carriage. While disease surveillance is limited and data are often lacking, MenB is an important serogroup associated with IMD and carriage in a number of countries. Available literature suggests that most pilgrims receive polysaccharide MenACWY vaccines (which do not impact carriage and onward transmission) and incomplete compliance with visa/entry immunization regulations is reported. Existing preventative approaches for visiting pilgrims require continued oversight. More complete compliance and switching to the conjugated MenACWY vaccine can provide more robust and broader protection for pilgrims. Additional immunization options could also be considered. Graphical Plain Language Summary

24 July 2021 in Expert Review of Vaccines
Verified
Journal Article
Open access
DSDebasish Saha
Debasish Saha
MOMartin O.C. Ota
Martin O.C. Ota
PPPriya Pereira
Priya Pereira
PBPhilippe Buchy
Philippe Buchy
SBselim badur
selim badur
What is the context? What is new? Why is this important?